Premier Partners
VC Fund
Seoul, South Korea
Premier Partners (프리미어 파트너스) is a Korean domestic funds management company. It provides investment services for individuals and businesses. Premier Partners was established in September 2005 in Seoul, Korea.
- Total investments:
- 195
- Last investment:
- Lead investor:
- 12%
- Fund size:
- $83M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Premier Partners invests in
Stages Premier Partners invests in
Countries Premier Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $2.6M–$15M
- Series B
- $5.8M–$45M
- Venture - Series Unknown
- $15M–$172M
Investment Focus
Industry
- Health Care 35 (18%)
- Biotechnology 31 (16%)
- Medical 22 (11%)
- Artificial Intelligence 20 (10%)
- Software 17 (9%)
Stage
- Venture - Series Unknown 57 (29%)
- Series B 48 (25%)
- Series A 34 (17%)
- Series C 26 (13%)
- Funding Round 14 (7%)
Country
- South Korea 137 (70%)
- United States 11 (6%)
- Russian Federation 2 (1%)
- United Kingdom 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Donghoon Jeon
Principal
|
Principal | Total investments: 0 | Find email | |
Hayoung Yun
Director
|
Director | Total investments: 2 | Find email | |
Hyun-moo Cho
Director
|
Director | Total investments: 1 | Find email | |
Jason Oh
Principal
|
Principal | Total investments: 0 | Find email | |
|
Jay Song
CEO; Chief Executive Officer
|
CEO; Chief Executive Officer | Total investments: 1 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| HITS is a biotech company that creates digital solutions to accelerate drug development and introduce a new drug discovery paradigm. The company creates a cloud-based drug development platform that connects AI models with docking and molecular dynamics. | $13.5M / Series B / Sep 28, 2026 | ||
| Prazer Therapeutics assists patients suffering from intractable diseases through the use of logical and innovative drug design approaches. They willaccomplished this through the use of new and innovative drug development platforms, such as rational molecular drug design technology and next-generation protein degradation technology. | $33.9M / Venture - Series Unknown / Jul 23, 2026 | ||
| FNCT Biotech develops antibody therapeutics for treating idiopathic pulmonary fibrosis (IPF). To create antibodies that target the underlying cause of IPF, the company's platform uses genetic engineering, providing patients with this medical need with a new treatment option. | $14M / Series B / Jun 16, 2026 | ||
Akisostem BioStrategies
|
Archisostem BioStrategies is a research and development company. | $2.7M / Series A / Jun 01, 2026 | |
| XCENA is a semiconductor company that develops data-centric computing systems designed for AI and large-scale data processing environments. The company builds computational memory technology that combines high-capacity pooled DDR5 memory with near-data processing capabilities, allowing computation to occur closer to where data is stored. Its coreplatform is based on the Compute Express Link (CXL) standard, which enables memory expansion beyond traditional CPU limitations while improving data movement efficiency and reducing latency in data center workloads. XCENA’s architecture is designed to support applications such as artificial intelligence workloads, vector databases, and large-scale analytics by addressing memory bandwidth and capacity constraints. The company provides a hardware-software ecosystem that includes computational memory systems and a full-stack software development kit. This SDK offers APIs, runtime tools, and drivers that allow applications to use computational memory without major changes to existing software architectures while also supporting low-level control for performance optimization.XCENA’s flagship product line includes MX1, a CXL-based computational memory solution that integrates near-data processing engines with memory infrastructure to support AI inference and data-intensive workloads. The platform is designed to improve throughput and scalability in environments where traditional memory architectures become a bottleneck. The company operates in the broader field of AI infrastructure and memory innovation, working with customers such as hyperscalers, telecom providers, and research institutions that manage large-scale computing workloads. Its solutions are intended to improve efficiency in systems handling AI, big data processing, and scientific computing. | $135M / Series B / May 29, 2026 | ||
| Asteromorph is an artificial intelligence (AI) research startup for the development of scientific superintelligence | $31.3M / Seed / May 29, 2026 | ||
| Upstage AI develops artificial intelligence technologies focused on large language models and document processing systems designed to support enterprise workflows. Its platform includes tools that convert unstructured data such as PDFs, scans, and emails into structured, machine-readable formats, enabling downstream analysis and automation. Thecompany also provides models like its Solar LLM, which are optimized for tasks such as text generation, information extraction, and question answering within business environments. Its solutions are applied across industries including finance, healthcare, insurance, and manufacturing to handle tasks like document parsing, data extraction, and workflow automation. Additionally, its services can be deployed through APIs, cloud environments, or on-premise systems to integrate with existing enterprise infrastructure. | $121.7M / Series C / Apr 15, 2026 | ||
| Medi Whale seeks to achieve sustainable healthcare where every eye can truly be the window to one’s health with our world's first-of-its-kind 1-stop AI screening platform solution for cardiovascular, renal, metabolic risk assessment, and eye disease diagnosis. Our AI Platform was developed through several clinical collaborations (Korea,Singapore, India, UK, and other European datasets) using structured longitudinal event-based datasets for the development of our retinal biomarker engines. RetiCVD® (cardiovascular disease risk assessment): Developed using coronary artery calcium (CAC) score, CAC is recognized as the gold standard for precise CVD risk calculation. Our CVD engine predicts the presence of CAC and provides a stratified probabilistic risk based on US ASCVD and EU SCORE guidelines.RetiCKD® (chronic kidney disease risk assessment): Developed using eGFR and full lab panel, our CKD engine has been demonstrated to achieve better predictive capability as compared to eGFR or full panel analysis.RetiEYE®: Referable Eye Disease engine detects and flags common aging-related eye modalities such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract at its referable disease state.Medi Whale retinal-based systemic biomarkers have been clinically demonstrated to be non-inferior to current gold standards and are recognized by clinical and scientific communities with two Lancet Digital Health publications. | $13.3M / Series C / Mar 27, 2026 | ||
| Connext is developing biological therapeutics in the field of immuno-oncology and regenerative medicine. | $10M / Series C / Mar 16, 2026 | ||
| MustBio is a biotechnology company that leverages multi-antibody technology to develop therapeutics primarily in the field of immuno-oncology. The company was founded in 2021 and is based in Seoul, South Korea. | $23.3M / Series C / Mar 13, 2026 | ||
| See all 195 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Premier Partners invest in?
Premier Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Series B stage. Most of the 195 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Premier Partners's check size?
Premier Partners typically joins rounds of $2.6M–$15M at Series A, $5.8M–$45M at Series B and $15M–$172M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Premier Partners participates in.
How do I contact Premier Partners?
Public channels for Premier Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Premier Partners?
The team at Premier Partners includes Donghoon Jeon (Principal), Hayoung Yun (Director) and Hyun-moo Cho (Director), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
